Detailansicht

Wissensnetz

Person

Marino Venerito (1975-)

Arzt

Name	Marino Venerito
Zeit	1975- (Lebensdaten)
Ort	Francavilla Fontana, Apulien, Italien (Geburtsort) Sonstiges Ausland / Unbekanntes Land
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf)
Weitere Angaben	FA für Innere Medizin und Gastroenterologie; Universitätskllinikum Magdeburg, Universitätsklinik für Gastroenterologie, Hepatologie und Infektiologie, Leiter des Bereichs Gastrointestinale Onkologie
Datensatztyp	Person
GND-Nummer	143142216
Datensatz-ID	143142216
Beteiligt an alle anzeigen Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer Comparison of the management of Helicobacter pylori infection between the older and younger European populations Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC) Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC) Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study Gastroduodenale Ulkuskrankheit und Helicobacter pylori Autoimmungastritis Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: Experience from four tertiary centers Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison Proteomics signature of autoimmune atrophic gastritis: towards a link with gastric cancer Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ≥ 400 ng/ml : a matching-adjusted indirect comparison Advanced pancreatic ductal adenocarcinoma : moving forward Expression von Cyclooxygenasen (COX-1 und COX-2) und Lipoxygenase (5-LOX) in Nasenpolypen und Bronchialschleimhaut bei Patienten mit Asthma bronchiale, rezidivierender Polyposis nasi und Analgetikainteroleranz : Korrelation mit klinischen und funktionellen Parametern Review : prevention and management of gastric cancer Sicherheit und Effektivität der CT-gestützten HDR-Brachytherapie von abdominalen Lymphknotenmetastasen S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature Maintenance therapy with FOLFIRI after FOLFIRINOX for advanced pancreatic ductal adenocarcinoma : a retrospective single-center analysis Helicobacter pylori Infection: New Facts in Clinical Management Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection Recurrent diffuse gastric bleeding as a leading symptom of gastrointestinal AL amyloidosis Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany – a region at intermediate risk for gastric cancer Influence of laboratory-related and endoscopy-related factors on the assessment of serum pepsinogens and gastrin-17 Charakterisierung der atrophischen Gastritis in Abhängigkeit der Ätiologie und ihre Bedeutung als präneoplastische Kondition in der Ösophagus- und Magenkarzinogenese Charakterisierung der atrophischen Gastritis in Abhängigkeit der Ätiologie und ihre Bedeutung als präneoplastische Kondition in der Ösophagus- und Magenkarzinogenese Short-term - low-dose aspirin-induced gastric and duodenal erosions are not dependent on the Helicobacter pylori-infection, cyclooxygenase expression and prostaglandin E_tn2 levels

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Marino Venerito (1975-)

Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial

Sustained Clinical Response to Ivosidenib in Previously Treated Patients with Advanced Intrahepatic Cholangiocarcinoma Harboring an IDH1 R132 Mutation: Two Case Reports

Efficacy, safety and differential outcomes of immune‐chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: a multicenter real world cohort

Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer

Comparison of the management of Helicobacter pylori infection between the older and younger European populations

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)

Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis

Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice

Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study

Gastroduodenale Ulkuskrankheit und Helicobacter pylori

Autoimmungastritis

Atezolizumab plus bevacizumab in patients with advanced and progressing hepatocellular carcinoma: retrospective multicenter experience

Efficacy and safety of atezolizumab and bevacizumab in the real-world treatment of advanced hepatocellular carcinoma: Experience from four tertiary centers

Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison

Proteomics signature of autoimmune atrophic gastritis: towards a link with gastric cancer

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort

Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with hepatocellular carcinoma and alpha-fetoprotein ≥ 400 ng/ml : a matching-adjusted indirect comparison

Advanced pancreatic ductal adenocarcinoma : moving forward

Expression von Cyclooxygenasen (COX-1 und COX-2) und Lipoxygenase (5-LOX) in Nasenpolypen und Bronchialschleimhaut bei Patienten mit Asthma bronchiale, rezidivierender Polyposis nasi und Analgetikainteroleranz : Korrelation mit klinischen und funktionellen Parametern

Review : prevention and management of gastric cancer

Sicherheit und Effektivität der CT-gestützten HDR-Brachytherapie von abdominalen Lymphknotenmetastasen

S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study

NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization

The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature

Maintenance therapy with FOLFIRI after FOLFIRINOX for advanced pancreatic ductal adenocarcinoma : a retrospective single-center analysis

Helicobacter pylori Infection: New Facts in Clinical Management

Combined Systemic Chemotherapy and CT-Guided High-Dose-Rate Brachytherapy for Isolated Local Manifestation of Pancreatic Cancer after Surgical Resection

Recurrent diffuse gastric bleeding as a leading symptom of gastrointestinal AL amyloidosis

Prevalence of Helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany – a region at intermediate risk for gastric cancer

Influence of laboratory-related and endoscopy-related factors on the assessment of serum pepsinogens and gastrin-17

Charakterisierung der atrophischen Gastritis in Abhängigkeit der Ätiologie und ihre Bedeutung als präneoplastische Kondition in der Ösophagus- und Magenkarzinogenese

Charakterisierung der atrophischen Gastritis in Abhängigkeit der Ätiologie und ihre Bedeutung als präneoplastische Kondition in der Ösophagus- und Magenkarzinogenese

Short-term - low-dose aspirin-induced gastric and duodenal erosions are not dependent on the Helicobacter pylori-infection, cyclooxygenase expression and prostaglandin E_tn2 levels